Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

- Several Potential Catalysts Expected in Next Six Months -

BRISBANE, Calif., July 31 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the second quarter and six months ended June 30, 2008. InterMune reported a net loss for the second quarter of 2008 of $26.5 million, or $0.68 per share, compared with a net loss of $19.8 million, or $0.58 per share, in the second quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "The second quarter of 2008 was an exciting period for InterMune. We reported substantial progress on our collaboration with Roche with ITMN-191 (R7227) by reporting top-line results from our 14-day monotherapy study, reporting the successful completion of 13-week preclinical toxicology studies in two species that enable our Phase 2 studies and announcing the initiation of our 14-day study of ITMN-191 plus standard of care therapy."

Mr. Welch continued, "The next six months will be a very rich period in terms of data and milestones for InterMune. At the AASLD meeting in late October, we expect to present the results of our two completed clinical studies of ITMN-191 as well as the results of non-clinical studies of ITMN-191 in combination with direct antiviral compounds in the Roche portfolio. During the fourth quarter, we expect to announce top-line results from our on-going 14-day study of ITMN-191 plus standard of care therapy and in January of 2009, we expect to report top-line results from our Phase 3 CAPACITY program for pirfenidone in idiopathic pulmonary fibrosis, a fatal disease for which no treatments are approved."

Results for Second Quarter 2008

InterMune reported total revenue in the s
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... KONG , Aug. 26, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... Limited ("MO2"), an entity wholly owned by Mr. Yuen ... Company, has acquired the outstanding shares (the "Shares") of  ...
(Date:8/26/2015)... CA. (PRWEB) , ... August 26, 2015 , ... ... conferences to develop new business relationships with local sponsors in southern California. The Clinical ... facilitate their drug development processes and regulatory pathways., , ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... lesions are cancerous is described by University of Illinois researchers in the ... and photonics. , In “ Breast cancer diagnosis using spatial light interference microscopy ...
(Date:8/25/2015)... (PRWEB) , ... August 25, 2015 , ... One of ... -based Resilinc Corp., Bindiya Vakil, has been on a mission for the ... impact on global supply chain operations - from the two massive explosions that occurred ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... ,D+CAF(TM) Caffeine Test Strips, to Know for Sure, Studies show ... ... levels of caffeine, MONROVIA, Calif., Nov. 12 Ever wonder ... know for sure,with new D+CAF, the first ever do-it-yourself caffeine test strip ...
... Can Streamline the Procurement Process using,SciQuest,s Solutions, ... Inc., the global leader,empowering enterprises to realize ... formation of a strategic alliance with QIAGEN, ... Through the alliance,both companies will work together ...
... GAITHERSBURG, Md., Nov. 12 MaxCyte, Inc.,the pioneer ... it will be hosting a live discussion with ... assays for drug discovery.,The discussion is open to ... on,Thursday, November 13th from 2:00-3:00EST., One of ...
Cached Biology Technology:Is Your Decaf Really Decaf? 2SciQuest Announces Strategic Alliance with QIAGEN 2SciQuest Announces Strategic Alliance with QIAGEN 3SciQuest Announces Strategic Alliance with QIAGEN 4MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/20/2015)... OXFORD, CT ., Aug. 20, 2015 ... "Company"), a biometric authentication company focused on the growing ... wallet, announces it has joined The Smart Card Alliance ... the Smart Card Alliance and the Smart Card Alliance ... and visibility to industry peers and thought leaders promoting ...
(Date:8/12/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is proud to announce that iMedNet ... platform, has led the way to significant and unprecedented ...   Q2 2015 and Q1 2015 were, respectively, the ... sold in the company,s 15 year history.  In addition, ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... known to repair their tissues effortlessly, but can this capacity ... the Stem Cell Program at Boston Children,s Hospital suggests that ... is active in embryonic stem cells, researchers were able to ... tissues in a mouse model. The study also ...
... more than doubled in children and tripled in adolescents ... according to the Centers for Disease Control and Prevention. ... health concern since overweight and obese youth are at ... for adults. These new pediatric diseases include type-2 diabetes, ...
... A recent prospective, randomized, placebo-controlled clinical trial reports that ... a group of male veterans with epilepsy who were ... in Epilepsia , a journal of the International ... may help to prevent new vertebral fractures when taken ...
Cached Biology News:Researchers regrow hair, cartilage, bone, soft tissues 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 2For obese teen girls, aerobic exercise may trump resistance training in health benefits 3Calcium and vitamin D improve bone density in patients taking antiepileptic drugs 2
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... The steadylite plus assay system ... assay sensitivity, Designed for batch-processing ... for higher density microplates such ... Odor free, Convenient storage conditions ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
Biology Products: